Catalase-Related Allene Oxide Synthase, on a Biosynthetic Route to Fatty Acid Cyclopentenones: Expression and Assay of the Enzyme and Preparation of the 8R-HPETE Substrate.

Catalase-related allene oxide synthase (cAOS) is a hemoprotein that converts a specific fatty acid hydroperoxide to an unstable allene oxide intermediate at turnover rates in the order of 1000 per second. Fatty acid allene oxides are intermediates in the formation of cyclopentenone or hydrolytic products in marine systems, most notably the prostanoid-related clavulones. Although the key catalytic amino acid residues around the active site of cAOS are the same as in true catalases, cAOS does not react with hydrogen peroxide. cAOS occurs exclusively as the N-terminal domain of a naturally occurring fusion protein with a C-terminal lipoxygenase (LOX) domain that supplies the hydroperoxide substrate. In marine invertebrates, an 8R-LOX domain converts arachidonic acid to 8R-hydroperoxyeicosatetraenoic acid (8R-HPETE) and the cAOS domain forms an 8,9-epoxy allene oxide. The fusion protein from the sea whip octocoral Plexaura homomalla is the prototypical model with crystal structures of the individual domains. The cAOS (43kDa) expresses exceptionally well in Escherichia coli, with yields of up to 100mg/L. This article describes in detail expression and assay of the P. homomalla cAOS and two methods for the preparation of its 8R-HPETE substrate. Another article in this volume focuses on the P. homomalla 8R-LOX (Gilbert, Neau, & Newcomer, 2018).

P2Y6 receptors require an intact cysteinyl leukotriene synthetic and signaling system to induce survival and activation of mast cells.

Cysteinyl leukotrienes (cys-LTs) induce inflammatory responses through type 1 (CysLT1R) and type 2 (CysLT2R) cys-LT receptors and activate mast cells in vitro. We previously demonstrated that cys-LTs cross-desensitized IL-4-primed primary human mast cells (hMCs) to stimulation with the nucleotide uridine diphosphate (UDP). We now report that hMCs, mouse bone marrow-derived mast cells (mBMMCs), and the human MC line LAD2 all express UDP-selective P2Y6 receptors that cooperate with CysLT1R to promote cell survival and chemokine generation by a pathway involving reciprocal ligand-mediated cross-talk. Leukotriene (LT) D4, the most potent CysLT1R ligand, and UDP both induced phosphorylation of ERK and prolonged the survival of cytokine-starved hMCs and mBMMCs. ERK activation and cytoprotection in response to either ligand were attenuated by treatment of the cells with a selective P2Y6 receptor antagonist (MRS2578), which did not interfere with signaling through recombinant CysLT1R. Surprisingly, both UDP and LTD4-mediated ERK activation and cytoprotection were absent in mBMMCs lacking CysLT1R and the biosynthetic enzyme LTC4 synthase, implying a requirement for a cys-LT-mediated autocrine loop. In IL-4-primed LAD2 cells, LTD4 induced the generation of MIP-1beta, a response blocked by short hairpin RNA-mediated knockdown of CysLT1R or P2Y6 receptors, but not of CysLT2R. Thus, CysLT1R and P2Y6 receptors, which are coexpressed on many cell types of innate immunity, reciprocally amplify one another's function in mast cells through endogenous ligands.

Hepoxilins: a review on their enzymatic formation, metabolism and chemical synthesis.

This article reviews published evidence describing the enzymatic and nonenzymatic formation and the routes of metabolism of the hepoxilins. Also treated are the major approaches used for the chemical synthesis of these compounds and for some of their analogs.

Syntheses of leukotriene-derivatives.

Some general synthetic routes for the synthesis of cysteinyl-leukotriene derivatives derived from stable building blocks are described. D6-LTE4, a metabolically stable isotopically labelled mass spectrometric internal standard, 20-hydroxy-LTE4, the unnatural 6-epi-LTE4; LTE3, a LT-derivative with 2-amino-thiophenol as a modified "amino-acid" and 14,15-dehydro-LTA4 were prepared. The compounds were tested in a LT-inhibition assay using a monoclonal antibody.

The synthesis, release and action of leukotrienes in the isolated, unstimulated, buffer-perfused rat heart.

When the perfusion medium of an isolated, non-recirculating, Langendorff rat heart is changed from Krebs buffer to coronary effluent, a significant vasoconstriction (23%, P less than 0.005) is observed. In this study we have investigated the involvement of leukotrienes in this phenomenon. We have extracted and quantified leukotrienes C4, D4 and E4 in samples of coronary effluent taken at different times during the first 2 h of perfusion; the total amounts released during this time were 9, 5 and 32 pmol of LTC4, LTD4 and LTE4 respectively. We have used two different methods to prevent the action of the effluent leukotrienes on the heart. Firstly, we have blocked the leukotriene receptors in the heart, with FPL 55712 (3.8 microM), during perfusion with effluent and, secondly, we have perfused with coronary effluent which was collected in the presence of a leukotriene synthesis inhibitor, AA861 (1 microM). The addition of FPL 55712 to the effluent decreased the normally observed vasoconstriction such that after 30 min the coronary flow rate (CFR) was 114 +/- 3% (n = 6) compared with 66 +/- 1% (n = 7) with effluent alone (P less than 0.005). Effluent collected in the presence of AA861 also caused a decrease in the normally observed vasoconstriction such that by 30 min the CFR was still 88 +/- 2% (n = 6, P less than 0.005 compared to controls). We have confirmed the proposed involvement of leukotrienes in the effluent-induced vasoconstriction by investigating the effect of a mixture of the synthetic leukotrienes C4, D4 and E4, when each of them was present at the same concentration as measured in the coronary effluent; the vasoconstriction observed was superimposable upon that seen with effluent. This vasoactive effect of the leukotriene mixture was not secondary to a change in contractility, since this only decreased to 97 +/- 5% (n = 9) during the 30 min of the leukotriene infusion. Finally, we have studied the effects of the same two leukotriene blockers in normal, buffer-perfused hearts after an initial perfusion of either 30 or 120 min. Application of either AA861 or FPL 55712 resulted in a dramatic vasodilatation (25 to 45% increase), a larger effect always being observed after the shorter initial period of perfusion. Our conclusions are two-fold. Firstly, isolated, buffer-perfused rat hearts synthesize leukotrienes C4, D4 and E4 in considerable amounts and release them into the coronary effluent and secondly, the coronary flow rates of isolated, buffer-perfused rat hearts are partly controlled by the action of internally produced leukotrienes.

[Reverse phase high performance liquid chromatography in the synthesis of leukotrienes A4 and C4]. / Obrashchenno-fazovaia vysokoéffektivnaia zhidkostnaia khromatografiia v sinteze leikotrienov A4 i C4.

The chromatographic (RP HPLC) behaviour of leukotriene C4, its methyl ester, leukotriene A4 methyl ester and some chemicals involved in their synthesis have been investigated. Optimal conditions of separation were determined for the gradient and isocratic HPLC. Parameters of the interaction of the substances with hydrophobic surface are discussed in terms of solvophobic theory.

11,12-leukotriene A4: synthesis and metabolism.

11(S),12(S)-oxido-5Z,7E,9E,14Z-eicosatetraenoic acid (11,12-LTA4) was chemically synthesized from 12-hydroperoxy-eicosatetraenoic acid (12-HPETE). 11,12-LTA4 methyl ester was nonenzymically hydrolyzed to at least four products. These products were identified to be epimers of 5,12(S)-dihydroxy-eicosatetraenoic acid methyl ester (5,12(S)-diHETE-Me) and epimers of 11,12-diHETE-Me. In addition to the above nonenzymic products, 11,12-LTA4 was converted to 11,12-LTC4 by the rat liver glutathione S-transferase, and to an isomer of 11,12-diHETE by homogenates of the guinea pig adrenal gland and liver.

HPLC studies on leukotriene A4 obtained from the hydrolysis of its methyl ester.

Alkaline hydrolysis of leukotriene A4 methyl ester to leukotriene A4 was studied in either methanol or acetone. Hydrolysis in acetone yielded larger amounts of leukotriene A4 than similar hydrolysis in methanol. The maximum amount was obtained 60 minutes after the beginning of the hydrolysis. Leukotriene A4, as well as leukotriene B4 methoxy isomers were obtained from hydrolysis of leukotriene A4 methyl ester in methanol. It was found that initial leukotriene A4 methyl ester concentration affected the amount of LTA4 produced during the hydrolysis. The maximum concentration of leukotriene A4 was obtained by hydrolyzing solutions of 0.25 mg/ml leukotriene methyl ester in acetone. Spontaneous degradation of leukotriene A4 occurred when it was diluted with tris buffer. Addition of bovine serum albumin to the tris buffer significantly prolonged the half life of leukotriene A4.

Synthesis and biological activity of new leukotriene antagonists (racemates and enantiomerically pure compounds).

Two series of structural analogues of leukotrienes C4, D4 and E4 (LTC4, LTD4, LTE4) were prepared. The compounds were evaluated for their ability to antagonize leukotriene-induced contractions of guinea pig lung strips. In comparison to FPL-55712, compounds 1a and 2h were more potent antagonists against LTC4 (2- and 3fold, respectively) and LTD4 (6- and 60fold respectively). Moreover, in vivo compounds 1a and 2h exhibited antagonism against leukotrienes (C4, D4, E4) and PAF, the most potent mediators in bronchial asthma. 2h also showed antagonistic activity when tested by inhalation.